Concepedia
7
Publications
549
Citations
H-Index
2020
Active since
Affiliations
Shionogi (United States)(Current)
University of California, San Francisco
BC Cancer Agency
UCSF Helen Diller Family Comprehensive Cancer Center
Novartis (United States)
Hemanth Kanakamedala is an author at Shionogi (United States) specializing in breast cancer, oncology, and cancer therapeutics.
Top concepts
MedicineOncologyPathologyPharmacologyBreast CancerCancer Therapy
Publications per year
2020–2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 340 citations
Breast Oncology, Oncology, Medicine +9
Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019
Jason M. Pogue, Yun Zhou, Hemanth Kanakamedala et al. · BMC Infectious Diseases · 2022 · 65 citations · Full text
No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)
Bin Cai, James A. Simon, Paola Villa et al. · Maturitas · 2020 · 45 citations · Full text
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer
Stuart Turner, Stephen Chia, Hemanth Kanakamedala et al. · The Oncologist · 2021 · 34 citations · Full text
Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia
Ryan K. Shields, Yun Zhou, Hemanth Kanakamedala et al. · BMC Infectious Diseases · 2021 · 30 citations · Full text
Rows per page
1–5 of 7